This is a preview of subscription content, log in via an institution to check access.
Notes
Ipilimumab, used to treat inoperable/metastatic melanoma, increases survival by about 2−6 months and costs about 880 000 krone per patient; abiraterone, used to treat metastatic prostate, prolongs life by about four months and costs 270 000 krone per patient.
Reference
Hansen A. Norway backs downs over plan to exclude anticancer drugs from coverage. BMJ 346: 14 Mar 2013. Available from: URL: http://dx.doi.org/10.1136/bmj.f1707
Rights and permissions
About this article
Cite this article
Norway will now reimburse ipilimumab and abiraterone. PharmacoEcon Outcomes News 674, 10 (2013). https://doi.org/10.1007/s40274-013-0259-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0259-z